{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:07:51Z","timestamp":1790784471511,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA045705"],"award-info":[{"award-number":["R01DA045705"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["R49-CE-003085"],"award-info":[{"award-number":["R49-CE-003085"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Drug overdose (OD) deaths in the U.S. continue to rise. After opioids, benzodiazepines (BZD) are the medication most commonly involved in prescription overdoses, yet OD risk factors among those prescribed BZD are not well understood. Our objective was to examine characteristics of BZD, opioid, and other psychotropic prescriptions associated with increased drug OD risk following a BZD prescription.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We completed a retrospective cohort study using a 20% sample of Medicare beneficiaries with prescription drug coverage. We identified patients with a BZD prescription (\u201cindex\u201d) claim between 1 April 2016 and 31 December 2017. In the 6\u00a0months pre-index, those without and with BZD claims comprised incident and continuing cohorts, which were split by age (incident\u2009&lt;\u200965 [<jats:italic>n<\/jats:italic>\u2009=\u2009105,737], 65\u2009+\u2009[<jats:italic>n<\/jats:italic>\u2009=\u2009385,951]; continuing\u2009&lt;\u200965 [<jats:italic>n<\/jats:italic>\u2009=\u2009 240,358], 65\u2009+\u2009[<jats:italic>n<\/jats:italic>\u2009=\u2009508,230]). Exposures of interest were: average daily dose and days prescribed of the index BZD; baseline BZD medication possession ratio (MPR) for the continuing cohort; co-prescribed opioids and psychotropics. Our primary outcome was a treated drug OD event (including accidental, intentional, undetermined, or adverse effect) within 30\u00a0days of the index BZD, examined using Cox proportional hazards.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among incident and continuing BZD cohorts, 0.78% and 0.56% experienced an OD event. Compared to 14\u201330\u00a0days, a\u2009&lt;\u200914-day fill corresponded to higher OD risk in incident (&lt;\u200965 adjusted hazard ratio [aHR] 1.16 [95% CI 1.03\u20131.31]; 65\u2009+\u2009: aHR 1.21 [CI 1.13\u20131.30]) and continuing (&lt;\u200965: aHR 1.33 [CI 1.15\u20131.53]; 65\u2009+\u2009: aHR 1.43 [CI 1.30\u20131.57]) cohorts. Among continuing users, lower baseline exposure (i.e., MPR\u2009&lt;\u20090.5) was associated with increased OD risk for those\u2009&lt;\u200965 (aHR 1.20 [CI 1.06\u20131.36]); 65\u2009+\u2009(aHR 1.12 [CI 1.01\u20131.24]). Along with opioids, concurrent antipsychotic use and antiepileptic use were associated with elevated risk of OD in all 4 cohorts (e.g., aHRs for the continuing 65\u2009+\u2009cohort: opioid, 1.73 [CI 1.58\u20131.90]; antipsychotic, 1.33 [CI 1.18\u20131.50]; antiepileptic, 1.18 [1.08\u20131.30]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In both the incident and continuing cohorts, patients dispensed fewer days' supply were at increased OD risk; those in the continuing cohort with more limited baseline BZD exposure were also at elevated risk. Concurrent medication exposures including opioids, antipsychotics, and antiepileptics were associated with short-term elevated OD risk.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-023-00674-x","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T22:01:48Z","timestamp":1684533708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prescription characteristics associated with drug overdose risk among adults prescribed benzodiazepines: a cohort study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-2640","authenticated-orcid":false,"given":"Donovan T.","family":"Maust","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S. B.","family":"Bohnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Strominger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Goldstick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"674_CR1","volume-title":"Drug Overdose Deaths in the U.S. Top 100,000 Annually","author":"National Center for Health Statistics, Centers for Disease Control and Prevention","year":"2021","unstructured":"National Center for Health Statistics, Centers for Disease Control and Prevention. Drug Overdose Deaths in the U.S. Top 100,000 Annually. 2021. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2021\/20211117.htm . Accessed 17 Dec 2021 ."},{"issue":"5","key":"674_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.amepre.2010.01.022","volume":"38","author":"JH Coben","year":"2010","unstructured":"Coben JH, Davis SM, Furbee PM, Sikora RD, Tillotson RD, Bossarte RM. Hospitalizations for poisoning by prescription opioids, sedatives, and tranquilizers. Am J Prev Med. 2010;38(5):517\u201324.","journal-title":"Am J Prev Med"},{"key":"674_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108609","volume":"221","author":"GA Bushnell","year":"2021","unstructured":"Bushnell GA, Olfson M, Martins SS. Sex differences in US emergency department non-fatal visits for benzodiazepine poisonings in adolescents and young adults. Drug Alcohol Depend. 2021;221: 108609.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"674_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/jama.2013.272","volume":"309","author":"CM Jones","year":"2013","unstructured":"Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657\u20139.","journal-title":"JAMA"},{"issue":"4","key":"674_CR5","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2105\/AJPH.2016.303061","volume":"106","author":"MA Bachhuber","year":"2016","unstructured":"Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996\u20132013. Am J Public Health. 2016;106(4):686\u20138.","journal-title":"Am J Public Health"},{"key":"674_CR6","unstructured":"National Institute on Drug Abuse, US Department of Health and Human Services. National Drug Overdose Deaths Involving Benzodiazepines, by Opioid Involvement, Number Among All Ages, 1999\u20132020. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates#:~:text=Drug%20overdose%20deaths%20involving%20benzodiazepines%20has%20steadily%20increased%20from%201%2C135,and%20rose%20again%20to%2012%2C290. Accessed August 4, 2022."},{"issue":"23","key":"674_CR7","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2017.15971","volume":"318","author":"D Dowell","year":"2017","unstructured":"Dowell D, Noonan RK, Houry D. Underlying factors in drug overdose deaths. JAMA. 2017;318(23):2295\u20136.","journal-title":"JAMA"},{"issue":"11","key":"674_CR8","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1111\/ajt.16053","volume":"21","author":"S Liu","year":"2021","unstructured":"Liu S, O\u2019Donnell J, Matt Gladden R, McGlone L, Chowdhury F. Trends in nonfatal and fatal overdoses involving benzodiazepines\u201438 states and the District of Columbia, 2019\u20132020. Am J Transplant. 2021;21(11):3794\u2013800.","journal-title":"Am J Transplant"},{"issue":"5","key":"674_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0269881114525674","volume":"28","author":"DS Baldwin","year":"2014","unstructured":"Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403\u201339.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"674_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jama.2017.6996","volume":"318","author":"MB Stein","year":"2017","unstructured":"Stein MB, Craske MG. Treating Anxiety in 2017: Optimizing Care to Improve Outcomes. JAMA. 2017;318(3):235\u20136.","journal-title":"JAMA"},{"issue":"4","key":"674_CR11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2019","unstructured":"American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674\u201394.","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"674_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJMra1611832","volume":"376","author":"M Soyka","year":"2017","unstructured":"Soyka M. Treatment of benzodiazepine dependence. New Engl J Med. 2017;376(12):1147\u201357.","journal-title":"New Engl J Med"},{"issue":"8","key":"674_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMp1715050","volume":"378","author":"A Lembke","year":"2018","unstructured":"Lembke A, Papac J, Humphreys K. Our other prescription drug problem. New Engl J Med. 2018;378(8):693\u20135.","journal-title":"New Engl J Med"},{"issue":"1\u20132","key":"674_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0740-5472(91)90024-5","volume":"8","author":"U Busto","year":"1991","unstructured":"Busto U, Sellers E. Pharmacologic aspects of benzodiazepine tolerance and dependence. J Subs Abuse Treat. 1991;8(1\u20132):29\u201333.","journal-title":"J Subs Abuse Treat"},{"key":"674_CR15","volume-title":"FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning","author":"U.S. Food and Drug Administration","year":"2016","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. 2016. https:\/\/www.fda.gov\/media\/99761\/download . Accessed 10 May 2019 ."},{"key":"674_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/CLEP.S105613","volume":"9","author":"KE Mues","year":"2017","unstructured":"Mues KE, Liede A, Liu J, Wetmore JB, Zaha R, Bradbury BD, et al. Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. Clin Epidemiol. 2017;9:267.","journal-title":"Clin Epidemiol"},{"issue":"Suppl 1","key":"674_CR17","doi-asserted-by":"publisher","first-page":"i56","DOI":"10.1136\/injuryprev-2019-043521","volume":"27","author":"A Vivolo-Kantor","year":"2021","unstructured":"Vivolo-Kantor A, Pasalic E, Liu S, Martinez PD, Gladden RM. Defining indicators for drug overdose emergency department visits and hospitalisations in ICD-10-CM coded discharge data. Inj Prev. 2021;27(Suppl 1):i56\u201361.","journal-title":"Inj Prev"},{"key":"674_CR18","unstructured":"U.S. Centers for Disease Control and Prevention. ICD-10-CM Official Guidelines for Coding and Reporting: FY2020. https:\/\/www.cdc.gov\/nchs\/data\/icd\/10cmguidelines-FY2020_final.pdf. Accessed 31 Aug 2022."},{"key":"674_CR19","doi-asserted-by":"crossref","unstructured":"Jones JL, Malcolm R. Neurobiology and Treatment of Sedative-, Hypnotic-, and Anxiolytic-Related Disorders. In: Brady KT, Levin FR, Galanter M, Kleber HD, editors. The American Psychiatric Association Publishing Textbook of Substance Use Disorder Treatment. Washington, DC; 2021:295.","DOI":"10.1176\/appi.books.9781615373970.kb20"},{"issue":"6","key":"674_CR20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1176\/appi.ajp.158.6.892","volume":"158","author":"PS Wang","year":"2001","unstructured":"Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatr. 2001;158(6):892\u20138.","journal-title":"Am J Psychiatr"},{"issue":"14","key":"674_CR21","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1001\/archinte.164.14.1567","volume":"164","author":"AK Wagner","year":"2004","unstructured":"Wagner AK, Zhang F, Soumerai SB, Walker AM, Gurwitz JH, Glynn RJ, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Int Med. 2004;164(14):1567\u201372.","journal-title":"Arch Int Med"},{"issue":"1","key":"674_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327.","journal-title":"Med Care"},{"issue":"10206","key":"674_CR23","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0140-6736(19)31786-6","volume":"394","author":"EO Hoogendijk","year":"2019","unstructured":"Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet. 2019;394(10206):1365\u201375.","journal-title":"Lancet"},{"issue":"7","key":"674_CR24","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","volume":"73","author":"DH Kim","year":"2018","unstructured":"Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring frailty in Medicare data: development and validation of a claims-based frailty index. J Gerontol: Series A. 2018;73(7):980\u20137.","journal-title":"J Gerontol: Series A"},{"issue":"8","key":"674_CR25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/gerona\/gly197","volume":"74","author":"DH Kim","year":"2019","unstructured":"Kim DH, Glynn RJ, Avorn J, Lipsitz LA, Rockwood K, Pawar A, et al. Validation of a claims-based frailty index against physical performance and adverse health outcomes in the health and retirement study. J Gerontol: Series A. 2019;74(8):1271\u20136.","journal-title":"J Gerontol: Series A"},{"key":"674_CR26","doi-asserted-by":"crossref","unstructured":"Hern\u00e1n M\u00c1, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561\u201370.","DOI":"10.1097\/00001648-200009000-00012"},{"issue":"12","key":"674_CR27","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1111\/jgs.14379","volume":"64","author":"DT Maust","year":"2016","unstructured":"Maust DT, Kales HC, Wiechers IR, Blow FC, Olfson M. No end in sight: benzodiazepine use in older adults in the United States. J Am Geriatr Soc. 2016;64(12):2546\u201353.","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"674_CR28","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.2105\/AJPH.2016.303382","volume":"106","author":"CN Kaufmann","year":"2016","unstructured":"Kaufmann CN, Spira AP, Depp CA, Mojtabai R. Continuing versus new prescriptions for sedative-hypnotic medications: United States, 2005\u20132012. Am J Public Health. 2016;106(11):2019\u201325.","journal-title":"Am J Public Health"},{"key":"674_CR29","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale: L. Erlbaum Associates; 1988."},{"key":"674_CR30","doi-asserted-by":"publisher","unstructured":"Chen H, Cohen P, Chen S. How Big is a Big Odds Ratio? Interpreting the Magnitudes of Odds Ratios in Epidemiological Studies, Communications in Statistics\u2014Simulation and Computation\u00ae. 2010;39(4):860\u20134. https:\/\/doi.org\/10.1080\/03610911003650383.","DOI":"10.1080\/03610911003650383"},{"issue":"2","key":"674_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1176\/appi.ps.201800321","volume":"70","author":"DT Maust","year":"2018","unstructured":"Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv. 2018;70(2):97\u2013106.","journal-title":"Psychiatr Serv"},{"issue":"7","key":"674_CR32","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1176\/appi.ajp.2020.20081174","volume":"178","author":"KY Xu","year":"2021","unstructured":"Xu KY, Borodovsky JT, Presnall N, Mintz CM, Hartz SM, Bierut LJ, et al. Association between benzodiazepine or Z-drug prescriptions and drug-related poisonings among patients receiving buprenorphine maintenance: a case-crossover analysis. Am J Psychiatr. 2021;178(7):651\u20139.","journal-title":"Am J Psychiatr"},{"key":"674_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j760","volume":"356","author":"EC Sun","year":"2017","unstructured":"Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356: j760.","journal-title":"BMJ"},{"key":"674_CR34","doi-asserted-by":"crossref","unstructured":"Cho J, Spence MM, Niu F, Hui RL, Gray P, Steinberg S. Risk of overdose with exposure to prescription opioids, benzodiazepines, and non-benzodiazepine sedative-hypnotics in adults: a retrospective cohort study. J Gen Intern Med. 2020;35(3):696\u2013703.","DOI":"10.1007\/s11606-019-05545-y"},{"key":"674_CR35","doi-asserted-by":"publisher","first-page":"h2698","DOI":"10.1136\/bmj.h2698","volume":"350","author":"TW Park","year":"2015","unstructured":"Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350(jun10 9):h2698.","journal-title":"BMJ"},{"issue":"12","key":"674_CR36","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1007\/s11606-018-4670-9","volume":"33","author":"DT Maust","year":"2018","unstructured":"Maust DT, Lin LA, Blow FC, Marcus SC. County and physician variation in benzodiazepine prescribing to medicare beneficiaries by primary care physicians in the USA. J Gen Int Med. 2018;33(12):2180\u20138.","journal-title":"J Gen Int Med"},{"issue":"jun10 9","key":"674_CR37","doi-asserted-by":"publisher","first-page":"h2698-h","DOI":"10.1136\/bmj.h2698","volume":"350","author":"TW Park","year":"2015","unstructured":"Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert ASB. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350(jun10 9):h2698-h.","journal-title":"BMJ."},{"issue":"4","key":"674_CR38","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jama.2020.22106","volume":"325","author":"ME Hirschtritt","year":"2021","unstructured":"Hirschtritt ME, Olfson M, Kroenke K. Balancing the risks and benefits of benzodiazepines. JAMA. 2021;325(4):347\u20138.","journal-title":"JAMA"},{"issue":"1","key":"674_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.mm6801a1","volume":"68","author":"JP VanHouten","year":"2019","unstructured":"VanHouten JP, Rudd RA, Ballesteros MF, Mack KA. Drug Overdose Deaths Among Women Aged 30\u201364 Years - United States, 1999\u20132017. Mmwr-Morbid Mortality Wkly Report. 2019;68(1):1\u20135.","journal-title":"Mmwr-Morbid Mortality Wkly Report"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00674-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-023-00674-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00674-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T22:03:01Z","timestamp":1684533781000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-023-00674-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1186\/s40360-023-00674-x","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"assertion":[{"value":"19 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This secondary data analysis was approved with a waiver of informed consent by the University of Michigan Medical School IRB (HUM00142565). The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"n\/a.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}